Oct 31Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024
Sep 3Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024
Aug 6Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update
Aug 1Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024
May 14Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
May 9Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
Apr 11Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
Feb 1Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
Jan 8Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders
Dec 20, 2023Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett Syndrome
Nov 24, 2023Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023
Sep 14, 2023Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease
Jun 28, 2023Long-term Clinical Study Demonstrates Disease-Modifying Effects of ANAVEX®2-73 for Rett Syndrome
Jun 20, 2023Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference